Wealthcare Advisory Partners LLC Reduces Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Wealthcare Advisory Partners LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,364 shares of the company’s stock after selling 207 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in Zoetis were worth $861,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC boosted its position in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares during the period. Independence Bank of Kentucky increased its stake in Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Ramirez Asset Management Inc. bought a new stake in shares of Zoetis during the third quarter worth $35,000. First Financial Corp IN grew its holdings in shares of Zoetis by 57.2% in the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after purchasing an additional 79 shares during the last quarter. Finally, Bogart Wealth LLC boosted its position in Zoetis by 188.9% in the 3rd quarter. Bogart Wealth LLC now owns 260 shares of the company’s stock valued at $45,000 after buying an additional 170 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $6.39 during midday trading on Wednesday, reaching $162.06. The company’s stock had a trading volume of 761,286 shares, compared to its average volume of 3,152,585. The firm has a market capitalization of $73.95 billion, a PE ratio of 32.46, a P/E/G ratio of 2.57 and a beta of 0.86. The stock has a fifty day moving average of $167.64 and a 200 day moving average of $178.93. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $1.31 EPS. On average, equities analysts expect that Zoetis Inc. will post 5.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 363 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ZTS shares. Barclays reduced their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Stifel Nicolaus cut their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group reduced their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $212.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.